COVID-19

January 18, 2021

SARS-CoV-2 encephalitis is a cytokine release syndrome: evidence from cerebrospinal fluid analyses | Evolution of antibody immunity to SARS-CoV-2 | Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

January 11, 2021

SARS-CoV-2 Viral Load on Admission Is Associated With 30-Day Mortality | Cognitive deficits in people who have recovered from COVID-19 relative to controls: An N=84,285 online study | Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Viral Research Lab Setting

January 4, 2021

Reports of “Long-COVID”, are rising: Attributes and predictors of “Long COVID” | Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity | More people are getting COVID-19 twice, suggesting immunity wanes quickly in some | Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19 | ApoE isoform-dependent SARS-CoV-2 neurotropism and cellular response

December 28, 2020

A distinct innate immune signature marks progression from mild to severe COVID-19 | Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19 | Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection

December 22, 2020

Veterans Health Administration COVID-19 (VACO) Index for COVID-19 Mortality | V-safe After Vaccination Health Checker | COVID-19 Vaccines and Severe Allergic Reactions | FDA Issues Emergency Use Authorization for Second COVID-19 Vaccine | K reports new variant, termed VUI 202012/01

December 14, 2020

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK | FDA issues Emergency Use Authorization for first COVID-19 vaccine

December 7, 2020

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 | The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020 | Updated CDC guidance on when to quarantine

November 30, 2020

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19 | Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results | Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19 | A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

November 23, 2020

Immunological memory to SARS-CoV-2 assessed for greater than six months after infection | Sixty-Day Outcomes Among Patients Hospitalized With COVID-19 | Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany | FDA Authorizes First COVID-19 Test for Self-Testing at Home

November 16, 2020

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans | Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study | FDA Authorizes Monoclonal Antibody for Treatment of COVID-19

Parasites Without Borders

A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.

Donate to Parasites Without Borders today!

Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States. 

Scroll to Top